Floatz logo

ABATACEPT RECOMBINANT

Beta Thalassemia

National Heart, Lung, and Blood Institute (NHLBI)protein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Beta Thalassemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Memorial Sloan Kettering Cancer Center
Phase 2BB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2B
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
Busulphan
New York Medical College
Phase 2B
Evomela
New York Medical College
Phase 2B

View all 19 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →